|
Palatin Obtains $21.1M to Advance Programs in Female Sexual Dysfunction and Asthma
Genetic Engineering News It intends to use the proceeds for working capital and general corporate purposes including its clinical trial program with bremelanotide for female sexual dysfunction (FSD), its PL-3994 programs for asthma, and for the preclinical development of … |
View full post on asthma – Google News